

COVID-19 Vaccine Dosing Recommendations

Primary Series (Monovalent Vaccine)

Pfizer/BioNTech

6 months-<5 years old: 3 mcg Monovalent IM at 0 and 3 weeks, then 3 mcg **Bivalent** IM given as the 3rd dose ≥8 weeks after dose 2

5-11 years old: 10 mcg IM at 0 and 3 weeks

≥12 years old: 30 mcg IM at 0 and 3-8¹ weeks

(Immunocompromised² persons ≥5 years old: 3rd primary dose ≥4 weeks after the 2nd)

-OR-

Moderna

6 months-5 years old: 25 mcg IM at 0 and 4 weeks

6-11 years old: 50 mcg IM at 0 and 4 weeks

≥12 years old: 100 mcg IM at 0 and 4-8² weeks

(Immunocompromised² persons: 3rd primary dose ≥4 weeks after the 2nd)

6 mos-4 years old →

5 - <6 years old →

6 - 11 years old →

≥12 years old →

≥12 years old →

≥18 years old →

Booster Dose¹

- Children who received a primary series with 3 Pfizer monovalent doses should receive 1 booster dose of Pfizer 3 mcg **BIVALENT**
- Children who received 2 Pfizer monovalent doses and 1 bivalent dose as their 3-dose primary series are not eligible for a booster at this time
- Children who received 2 doses of Moderna monovalent as their primary series should receive 1 booster dose of Moderna 10 mcg **BIVALENT**

≥2 months after primary series

- 1 dose of Pfizer/BioNTech 10 mcg **BIVALENT** if Pfizer was primary series
- 1 dose Moderna 10 mcg **BIVALENT** if Moderna was primary series

≥2 months after primary series or most recent monovalent booster

One dose of Pfizer/BioNTech 10 mcg **OR** Moderna 25 mcg **BIVALENT**
≥2 months after primary series or most recent monovalent booster

One dose of Pfizer/BioNTech 30 mcg **OR** Moderna 50 mcg **BIVALENT**[†]
≥2 months after primary series or most recent monovalent booster

One dose of Pfizer/BioNTech 30 mcg **OR** Moderna 50 mcg **BIVALENT**[†]
≥2 months after primary series or most recent monovalent booster

Pfizer/BioNTech 30 mcg **OR** Moderna 50 mcg **BIVALENT**[†]
≥2 months after primary J&J immunization (≥2 months after mRNA dose in immunocompromised patients³) or most recent monovalent booster

Bivalent Boosters

- CDC recommends use of bivalent boosters regardless of number of previous booster doses given
- Pfizer/BioNTech and Moderna bivalent booster doses contain mRNA components of the original virus and a common component of BA.4 and BA.5 (lineages of the Omicron variant)

Novavax Monovalent Booster

[†] In persons ≥18 years old who have not previously received a COVID-19 booster vaccine dose and who are unable to receive an mRNA vaccine, a Novavax monovalent booster dose may be given ≥6 months after a primary series

Novavax

≥12 years old: 0.5 mL IM at 0 and 3 weeks

Johnson & Johnson*

≥18 years old: 0.5 mL (5x10¹⁰ viral particles) IM once

(Immunocompromised² : 1 dose of mRNA vaccine ≥4 weeks after 1st J&J dose)

*FDA limits use to only those who are unable or unwilling to receive an mRNA vaccine (Pfizer/BioNTech or Moderna) because of thrombosis with thrombocytopenia syndrome (TTS) risk

- An 8-week interval may be optimal for certain persons ≥12 years old, especially males 12-39 years old. A standard 3- (Pfizer/BioNTech) or 4- (Moderna) week interval between the first two doses should still be used in adults ≥65 years old, persons who are moderately or severely immunocompromised, and other persons who require more rapid protection because of high levels of community spread of SARS-CoV-2 infection or a high risk of severe COVID-19. See: <https://bit.ly/38i7CIH>.
- Immunocompromised: active cancer treatment (solid tumors or hematologic), organ transplant, stem cell transplant within the last 2 years, moderate or severe primary immunodeficiency, advanced or untreated HIV infection, high-dose corticosteroids (≥ 20 mg prednisone/day or equivalent), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, severely immunosuppressive chemotherapy, TNF blockers, other immunosuppressive or immunomodulatory biologic agents.
- In persons who received an initial J&J dose and already received a booster dose (Pfizer/BioNTech, Moderna [50 mcg, 0.25 mL], or J&J), without having had the 2nd (additional) mRNA vaccine dose, a Pfizer/BioNTech vaccine or a Moderna vaccine (100 mcg [0.5 mL]) should be administered as the 3rd dose at least 2 months after dose 2, regardless of type and timing of vaccine received as the 2nd dose.